Afghanistan vs New Zealand: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage
Afghanistan
57.0%
in 2024
New Zealand
60.0%
in 2024
Afghanistan rank
136th
New Zealand rank
133rd
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage over time
- Afghanistan
- New Zealand
How they compare
New Zealand currently reports 60.0% against 57.0% in Afghanistan, a difference of 3.0%.
That makes New Zealand's figure about 1.1 times Afghanistan's.
Across all 11 years both countries report, New Zealand has been ahead every year.
Afghanistan ranks 136th and New Zealand ranks 133rd of 146 countries.
New Zealand has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Afghanistan | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 60.5% | 93.3% | 32.8% | New Zealand |
| 2020s | 56.4% | 81.2% | 24.8% | New Zealand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage, Afghanistan or New Zealand?
- New Zealand, at 60.0% against 57.0% in Afghanistan as of 2024.
- What is the difference in pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage between Afghanistan and New Zealand?
- 3.0%, with New Zealand ahead.
- How many years of comparable data are there for Afghanistan and New Zealand?
- 11 years are reported by both, from 2014 to 2024.
- How do Afghanistan and New Zealand rank globally for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- Afghanistan ranks 136th and New Zealand ranks 133rd of 146 countries.
- Where does this data come from?
- WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.